Zyga Technology, based in Minnetonka, Minn., develops minimally invasive solutions for underserved areas of the lumbar spine. The company has developed two products: the SImmetry Sacroiliac Joint Fusion System, which uses joint decortication, bone grafting and fixation with a threaded implant to achieve SI joint arthrodesis, and the Glyder Facet Restoration Device, a minimally invasive non‑fusion option for patients with facet joint pain. Led by President and CEO Jim Bullock, Zyga focuses on procedural solutions rather than pharmaceuticals. The company completed a $10M financing comprised of $8M in debt and $2M in equity, with Silicon Valley Bank as the sole debt provider and the equity supported by existing major investors. Zyga intends to use the proceeds to expand its U.S. sales and marketing organization and to support three U.S. clinical studies: EVSI, SAIF and DUET. Zyga Technology develops and markets minimally invasive surgical solutions for conditions of the spine. The company is commercializing its SImmetry® Sacroiliac Joint Fusion System and is trialling its GLYDER(TM) facet resurfacing product. Zyga intends to use recent funding to expand its clinical efforts. Those clinical efforts are aimed at securing CE Mark clearance and US trial approval. The company is led by CEO and President Jim Bullock. The financing will support the company’s regulatory and commercialization activities.

Total raised

$35M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Sep 2014